Cutting edge two-photon microscopy system breaks new grounds in retinal imaging

May 20, 2020

Retina is the only part of the central nervous system (CNS) that can be visualized noninvasively with optical imaging approaches. Direct retinal imaging plays an important role not only in understanding diseased eye and ocular therapeutic discovery, but also study of a variety of well-defined CNS disorders. Accumulated evidences have shown that certain neurodegenerative diseases that affect the brain and spinal cord also have manifestations in the retina, and ocular symptoms always precede traditional diagnosis of such diseases, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.

But as prevalent retinal imaging tools provide limited resolution, photos taken previously are often inadequate to resolve the subcellular structures and dynamics of retinal neurons, mainly attributed to the large optical aberrations of the living eye.

In a recent breakthrough, a team of scientists at the Hong Kong University of Science and Technology developed an adaptive optics two-photon excitation fluorescence microscopy (AO-TPEFM) using direct wavefront sensing for high-resolution in vivo fluorescence imaging of mouse retina, which allow in vivo fundus imaging at an unprecedented resolution after full AO correction. The advance will provide a much-needed tool to study biological processes in retina, and would also shed new light on the neurodegenerative diseases in the central nervous system (CNS).

Their work was published in the journal Light: Science & Applications on May 6, 2020.

"In this work, we advance two-photon microscopy for near-diffraction-limited and functional retinal imaging in living mice," said Prof. Jianan QU, lead researcher and Professor at the Department of Electronic and Computer Engineering, HKUST. "The localized two-photon fluorescence signals were used as nonlinear guide stars to achieve accurate measurement of ocular aberrations at the imaging location. We demonstrate that depth-resolved structures in different retinal layers can be resolved allowing for a wide range of studies which are infeasible otherwise."

AO is a technology used to improve the performance of an optical system by deforming a mirror in order to correct for the distortion(s). AO was first invented to remove the effects of atmospheric distortion in astronomical telescopes and laser communication systems.

In addition to enabling simultaneously functional calcium imaging of somas and dendrites of RGCs, AO-TPEFM also achieves precise axotomy and time-lapse imaging of axonal degeneration with femtosecond laser induced microsurgery.

"Direct wavefront sensing based on nonlinear fluorescent guide stars would be advantageous for accurate measurement of ocular aberrations at the exact imaging location, and thus permits highly efficient AO correction." said Prof. Qu. "As the technology is more widely deployed, AO-TPEFM could help investigate the development of neurodegenerative diseases, since the eye offers a window into nerves of the central nervous system that link the eye with the brain."
-end-


Hong Kong University of Science and Technology

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.